Sandra Lord
13 Papers
2 Citations
Sandra Lord is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 7 publications.
Chat about Author
Papers
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jillian R. Jaycox,Carolina Lucas,Inci Yildirim,Yile Dai,Eric Wang,V. Monteiro,Sandra Lord,Jeffrey Carlin,Mariko Kita,Jane H. Buckner,Shuangge Ma,Melissa Campbell,Albert Ko,Saad B. Omer,Carrie L. Lucas,Cate Speake,Akiko Iwasaki,Aaron M. Ring +17 more
TL;DR: In this paper , Rapid Extracellular Antigen Profiling was used to characterize self-and viral-directed humoral responses after SARS-CoV-2 mRNA vaccination in 145 healthy individuals, 38 patients with autoimmune diseases, and 8 patients with mRNA vaccine-associated myocarditis.
The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes
Allison J. Greaney,Rachel Eguia,Tyler N. Starr,Khadija Khan,Nicholas Franko,Jennifer Logue,Sandra Lord,Cate Speake,Helen Y. Chu,Alex Sigal,Jesse D. Bloom +10 more
TL;DR: Deep mutational scanning is used to show that mutations to the RBD’s class 1 and class 2 epitopes, including sites 417, 478, and 484–486 often reduce binding of these Delta-elicited antibodies, which helps elucidate how the antigenic impacts of SARS-CoV-2 mutations depend on exposure history.
21
OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals.
Alyssa Ylescupidez,Cate Speake,Susan L. Pietropaolo,Darrell M. Wilson,Andrea K. Steck,Jennifer L. Sherr,Jason L. Gaglia,Christine Bender,Sandra Lord,Carla J. Greenbaum +9 more
TL;DR: Every six-month CGM measures in multiple-AAB-positive individuals are predictive of subsequent T1D, but less so than OGTT derived variables.
18
IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function
Cate Speake,Tania Habib,Katharina Lambert,Christian Hundhausen,Sandra Lord,Matthew J. Dufort,Samuel O. Skinner,Alex Hu,Mackenzie Kinsman,Britta E. Jones,Megan D Maerz,Megan Tatum,Anne M. Hocking,Gerald T. Nepom,Carla J. Greenbaum,Jane H. Buckner +15 more
TL;DR: Findings indicate that the context of IL-6 blockade in vivo drives distinct T cell intrinsic changes that may influence therapeutic outcomes.
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
Alyssa Ylescupidez,Henry T Bahnson,Colin O’Rourke,Sandra Lord,Cate Speake,Carla J. Greenbaum +5 more
TL;DR: A standardized metric, Quantitative Response (QR), enhances clinical trial design and outcome interpretation in type 1 diabetes by adjusting for predictable disease course variables, reducing variance and increasing statistical power, and providing model-based estimates of treatment efficacy.
7